Effect of warfarin on activated partial thromboplastin time in patients receiving heparin

被引:38
作者
Kearon, C
Johnston, M
Moffat, K
McGinnis, J
Ginsberg, JS
机构
[1] Hamilton Civ Hosp, Res Ctr, Hamilton, ON, Canada
[2] McMaster Univ, Hamilton, ON, Canada
关键词
D O I
10.1001/archinte.158.10.1140
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The activated partial thromboplastin time (APTT) is used to adjust heparin sodium dosage. However, warfarin sodium is often administered concomitantly with heparin and may also affect the APTT and, therefore, heparin dose. We performed a prospective cohort study to quantify the effect of warfarin on the APTT in patients who are being treated with heparin. Methods: Serial assays of APTT, international normalized ratio, heparin levels, and functional levels of prothrombin (factor II) and factors VII and X were performed in 24 patients with acute venous thromboembolism who were treated with concomitant continuous intravenous heparin and warfarin. The effects of warfarin, as expressed-by international normalized ratio and coagulation factor levels, on APTT were determined. Results: Warfarin markedly affected APTT; for each increase of 1.0 in the international normalized ratio, the APTT increased 16 seconds (95% confidence interval, 10-22 seconds). The effects of warfarin and heparin on APTT were additive. Consequently, warfarin markedly altered the relationship between APTT and heparin levels; of the 29 blood samples with supratherapeutic APTT, 13 had a therapeutic heparin level and 10 had a subtherapeutic heparin level. Conclusions: In patients receiving concomitant heparin and warfarin therapy, APTT reflects the combined effects of both drugs. Because of the marked effect of warfarin on the APTT, decreasing heparin dose in response to a high APTT frequently results in subtherapeutic heparin levels.
引用
收藏
页码:1140 / 1143
页数:4
相关论文
共 16 条
[1]   The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin [J].
Anand, S ;
Ginsberg, JS ;
Kearon, C ;
Gent, M ;
Hirsh, J .
ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (15) :1677-1681
[2]  
BIGGS R, 1972, HUMAN BLOOD COAGULAT, P614
[3]   ESTABLISHING A THERAPEUTIC RANGE FOR HEPARIN-THERAPY [J].
BRILLEDWARDS, P ;
GINSBERG, JS ;
JOHNSTON, M ;
HIRSH, J .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (02) :104-109
[4]   A STANDARD HEPARIN NOMOGRAM FOR THE MANAGEMENT OF HEPARIN-THERAPY [J].
CRUICKSHANK, MK ;
LEVINE, MN ;
HIRSH, J ;
ROBERTS, R ;
SIGUENZA, M .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (02) :333-337
[5]  
EASTHAM RD, 1964, LANCET, V2, P543
[6]  
HAUSER VM, 1986, DRUG INTELL CLIN PHA, V2, P964
[7]  
HIRSH J, 1991, NEW ENGL J MED, V324, P1565
[8]   HEPARIN - MECHANISM OF ACTION, PHARMACOKINETICS, DOSING CONSIDERATIONS, MONITORING, EFFICACY, AND SAFETY [J].
HIRSH, J ;
RASCHKE, R ;
WARKENTIN, TE ;
DALEN, JE ;
DEYKIN, D ;
POLLER, L .
CHEST, 1995, 108 (04) :S258-S275
[9]   MECHANISM OF ACTION, CLINICAL EFFECTIVENESS, AND OPTIMAL THERAPEUTIC RANGE [J].
HIRSH, J ;
DALEN, JE ;
DEYKIN, D ;
POLLER, L ;
BUSSEY, H .
CHEST, 1995, 108 (04) :S231-S246
[10]   HEPARIN FOR 5 DAYS AS COMPARED WITH 10 DAYS IN THE INITIAL TREATMENT OF PROXIMAL VENOUS THROMBOSIS [J].
HULL, RD ;
RASKOB, GE ;
ROSENBLOOM, D ;
PANJU, AA ;
BRILLEDWARDS, P ;
GINSBERG, JS ;
HIRSH, J ;
MARTIN, GJ ;
GREEN, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (18) :1260-1264